Danaher Co. (NYSE:DHR) Shares Sold by Smith Anglin Financial LLC

Smith Anglin Financial LLC trimmed its position in Danaher Co. (NYSE:DHR) by 14.7% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 772 shares of the conglomerate’s stock after selling 133 shares during the period. Smith Anglin Financial LLC’s holdings in Danaher were worth $215,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Oak Thistle LLC bought a new position in Danaher in the second quarter worth about $363,000. Caden Capital Partners LP raised its holdings in shares of Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after buying an additional 15,313 shares during the last quarter. HighPoint Advisor Group LLC bought a new stake in shares of Danaher during the fourth quarter valued at approximately $2,614,000. Norden Group LLC bought a new stake in shares of Danaher during the first quarter valued at approximately $4,151,000. Finally, Duality Advisers LP bought a new stake in Danaher during the first quarter worth approximately $5,573,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $268.79 on Tuesday. The stock has a market cap of $199.09 billion, a P/E ratio of 45.56, a PEG ratio of 4.55 and a beta of 0.83. The company’s 50-day simple moving average is $271.07 and its 200 day simple moving average is $258.64. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.05 earnings per share. As a group, research analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s payout ratio is 18.31%.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,659 shares of company stock worth $11,042,433. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of several recent analyst reports. Barclays boosted their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 24th. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 target price on shares of Danaher in a report on Friday, September 6th. Robert W. Baird lifted their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Bank of America lifted their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, The Goldman Sachs Group lifted their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.